Related Experiment Video
Updated: Jun 5, 2025

Characterization of Sickling During Controlled Automated Deoxygenation with Oxygen Gradient Ektacytometry
Published on: November 5, 2019
The Voxelotor Effect: Decreased Affinity for New Drugs for Sickle Cell Disease?
Charles T Quinn1,2, Russell E Ware1,2,3
1Division of Hematology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Abstract:
Voxelotor (OXBRYTA) was abruptly withdrawn from the global market in September 2024. Clinicians and patients were not prepared for this, and the sudden discontinuation has caused much consternation, uncertainty, and loss of trust.
Related Concept Videos
Multiple Allele Traits
Desensitization and Tachyphylaxis
Drugs Affecting Neurotransmitter Release or Uptake
Dose-Response Relationship: Potency and Efficacy
Dose-Response Relationship: Selectivity and Specificity
Time Course of Drug Effect

